Current Affairs Topics Archive
International Relations Economics Polity & Governance Environment & Ecology Science & Technology Internal Security Geography Social Issues Art & Culture Modern History

Production Linked Incentive Scheme

March 20, 2026 4 min read Economics Polity & Governance GS2 GS3
On This Page ▼

What Happened

  • The Production Linked Incentive (PLI) scheme for Pharmaceuticals, approved by the Union Cabinet in February 2021, has attracted actual investment of Rs 27,453 crore — exceeding the committed target of Rs 17,275 crore — as of December 2023.
  • The scheme selected 55 applicants from 278 applications received against a financial outlay of Rs 15,000 crore.
  • It covers three product categories: biopharmaceuticals and complex generics (Category 1); Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) (Category 2); and other drugs (Category 3).
  • The scheme aims to reduce India's dependence on imported APIs — particularly from China — and diversify domestic pharmaceutical production toward high-value goods.
  • 20 of the 55 selected participants are MSMEs, reflecting the scheme's inclusive design.

Static Topic Bridges

Production Linked Incentive (PLI) Scheme Architecture

The PLI scheme is a supply-side industrial policy instrument that provides financial incentives to manufacturers based on incremental sales above a pre-defined base year. Unlike capital subsidies, PLI is output-linked — firms earn incentives only when they produce and sell more. The pharmaceuticals PLI is one of 14 sectors covered under the umbrella PLI programme approved under the Atmanirbhar Bharat strategy.

  • Operational guidelines for pharma PLI were issued on June 1, 2021 by the Department of Pharmaceuticals.
  • Incentive rates vary by product category and year (typically 3–10% of incremental sales over 6 years).
  • Category 1 (complex/high-value products) carries higher incentive rates than Category 3 (commodity generics).
  • The 14 PLI sectors span mobile phones, medical devices, auto components, textiles, solar PV, specialty steel, food processing, and white goods among others.
  • Nodal ministry for pharma PLI: Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers.

Connection to this news: The investment overrun (₹27,453 crore actual vs ₹17,275 crore committed) signals that industry confidence in the pharma sector's growth potential is higher than anticipated — a vindication of PLI as a policy design.

India's API Dependence and Import Vulnerability

Active Pharmaceutical Ingredients (APIs) are the biologically active components in medicines. India, despite being the world's largest supplier of generic medicines (supplying ~20% of global generic volume), is heavily dependent on China for about 70% of its API and KSM requirements. This supply chain vulnerability became visible during the COVID-19 pandemic when Chinese exports were disrupted.

  • India supplies 60% of global vaccine demand, 40% of US generic drugs, and 25% of UK medicines.
  • Bulk drugs (APIs) are a subclause of pharmaceutical manufacturing; a separate PLI scheme for bulk drugs (Rs 6,940 crore) runs parallel to the general pharma PLI to specifically incentivise API production.
  • Key therapeutic areas for API import dependence: antibiotics (penicillin, amoxicillin), vitamins (B1, B12, C), and antipyretics (paracetamol).
  • The Pharma Park scheme (three parks approved) complements PLI by providing plug-and-play infrastructure for API manufacturing clusters.

Connection to this news: Category 2 of the pharma PLI directly targets the API and KSM gap, aiming to rebuild domestic supply chains that were exposed as strategically vulnerable during COVID-19.

Atmanirbhar Bharat and Industrial Policy

Atmanirbhar Bharat (Self-Reliant India) was announced in May 2020 as a Rs 20 lakh crore economic package combining immediate relief measures with long-term structural reforms. Its industrial policy dimension centred on PLI schemes across 14 sectors, aimed at raising India's global manufacturing competitiveness and reducing import dependence in strategic goods. This represented a notable revival of active industrial policy after decades of liberal orthodoxy.

  • Total PLI outlay across 14 sectors: approximately Rs 1.97 lakh crore over 5 years.
  • Target: Add Rs 30 lakh crore in production and create 60 lakh jobs over five years.
  • Other manufacturing enablers: National Logistics Policy (2022), PM Gati Shakti (infrastructure master plan), Industrial Corridors.
  • Concern raised: PLI tends to favour large established firms and may not adequately benefit small manufacturers or generate proportionate employment relative to capital deployed.

Connection to this news: The pharma PLI's over-achievement on investment — and its inclusion of 20 MSMEs — addresses both the Atmanirbhar Bharat strategic goal (reduce import vulnerability) and the equity goal (MSME participation).

Key Facts & Data

  • Scheme: PLI for Pharmaceuticals; approved by Union Cabinet: February 24, 2021
  • Nodal ministry: Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers
  • Financial outlay: Rs 15,000 crore (over 6 years)
  • Applicants received: 278; selected: 55 (including 20 MSMEs)
  • Committed investment: Rs 17,275 crore; actual investment realised: Rs 27,453 crore (Dec 2023)
  • Three product categories: Biopharmaceuticals/complex generics (Cat 1), APIs/KSMs (Cat 2), Other drugs (Cat 3)
  • India's pharma exports: ~$27 billion annually; world's largest generic medicines supplier
  • China API dependence: ~70% of India's API/KSM requirements
  • A parallel PLI scheme for bulk drugs (APIs only): Rs 6,940 crore approved separately